{
    "clinical_study": {
        "@rank": "127827", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Active Comparator", 
                "description": "an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)"
            }
        ], 
        "brief_summary": {
            "textblock": "The proposed study is a randomized, double-blinded, non-placebo-controlled evaluation of the\n      effect of the addition of dexamethasone to intraoperative intercostal nerve block\n      bupivicaine solutions on the duration of pain relief and post operative pulmonary function."
        }, 
        "brief_title": "The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Minimally Invasive Thorascopic Surgical Pain", 
        "detailed_description": {
            "textblock": "Our study proposes two groups of 25 patients undergoing similar VATS surgery with a single\n      surgeon, Dr. R. McKenna, who will receive interoperatively placed intercostal nerve blocks\n      at the same levels. Each group will receive intercostals nerve blocks with one of two\n      different solutions: group one will receive intercostal nerve blocks with only 0.46%\n      bupivacaine (19.5 ml of 0.5% bupivacaine + .5 cc saline), group 2 will receive intercostal\n      blocks with 0.46% bupivacaine and dexamethasone(19.5 ml of 0.5% bupivacaine + .5ml .4%\n      dexamethasone). The patients will have pulmonary lung function objectively assessed by\n      portable spirometry and clinical factors both preoperatively and postoperatively. Our study\n      objective is to examine and quantify the potentially beneficial effects of intercostal nerve\n      blockade prolongation with dexamethasone on postoperative pulmonary function and\n      postoperative recovery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 - 80 years old of either gender, scheduled for unilateral VATS procedure with Dr.\n             McKenna for resection of lung tumor.\n\n        Exclusion Criteria:\n\n          -  ASA IV and above\n\n          -  Intolerance, allergy, or contraindication to use of any medications used in this\n             study\n\n          -  Significant coronary artery disease (abnormal stress test, myocardial infarction\n             within the last 3 months)\n\n          -  Uncontrolled hypertension (BP > 140/90)\n\n          -  History of prior ipsilateral thorascopic surgery\n\n          -  Cardiac arrhythmias particularly prolonged QT syndrome\n\n          -  Drugs known to cause prolonged qT: class IA antiarrhythmics (quinidine, procainamide,\n             dysopyramide), class III antiarrhythmics (sotalol, dofetalide, ibutalide,\n             amiodarone), haloperidol,  thioridazine, arsenic trioxide, HIV protease inhibitors,\n             tricyclic antidepressants\n\n          -  Individuals with significant psychological disorders including: schizophrenia, mania,\n             bipolar disorder or psychosis\n\n          -  Pregnant or lactating women\n\n          -  Morbid obesity (BMI > 40 kg/m2) AND/OR weight > 150 kg\n\n          -  Chronic renal failure ( creatinine > 2.0 mg/dL)\n\n          -  Liver failure e.g., active cirrhosis\n\n          -  Alcohol or substance abuse within in the past 3 months\n\n          -  Uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics,\n             mineralocorticoid use, laxatives)\n\n          -  Restrictive lung disease (pulmonary fibrosis, myasthenia gravis) or FEV1 or FEV less\n             than 70% of predicted value.\n\n          -  Type 2 diabetes\n\n          -  Neuropathic pain\n\n          -  Chronic opioid consumption (>30mg oxycodone or greater per day)\n\n          -  Cahexia from any cause\n\n          -  systemic use of corticosteroids for greater than 2 weeks in the 6 months prior to\n             surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005575", 
            "org_study_id": "Pro00032069"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 2", 
                "description": "The standard of care is to use a regional block solution containing both decadron and bupivicaine.", 
                "intervention_name": "Bupivacaine and Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Decadron"
            }, 
            {
                "arm_group_label": "Group 1", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bupivacaine", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90048"
                }, 
                "name": "Cedars Sinai Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Cedars Sinai Institutional Review Board"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be evaluated for post operative pain using the NRS pain evaulation", 
            "measure": "Post operative pain", 
            "safety_issue": "No", 
            "time_frame": "72 hours post operatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005575"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cedars-Sinai Medical Center", 
            "investigator_full_name": "dermot Maher", 
            "investigator_title": "Resident Department of Anesthesia", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Cedars-Sinai Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cedars-Sinai Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}